Comparing the FDA new drug approval lists from 2023 and 2024 reveals a significant difference in the size of the companies that achieved the regulatory triumphs. In 2023, among the 68 FDA approvals ...

Cost advantages concentrated in higher OOP tiers: only 15% of all prescriptions were cheaper, but MCCPDC undercut insurance for ~82% of fills when OOP exceeded $15. Therapeutic areas with frequent ...

Two-thirds of pharmaceutical companies did not proactively release the launch price of their medications from 2022 to 2024. Objective: To examine how drug manufacturers disclosed prices for new ...

Data on California’s commercial health care spending reinforce policies and strategies to improve consumer affordability.